Go online to PeerView.com/PHH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Management of triple-negative breast cancer (TNBC) has remained challenging for many years, with limited effective options and poor outcomes for most patients. But the tide is turning, as new therapies are emerging for this patient population, with immunotherapy representing a new pillar of care in the treatment of TNBC. TNBC is known to be more immunogenic compared with other breast cancer subtypes, and thus, immunotherapy has been and continues to be extensively explored in TNBC. Clinical trials have started to show promising results in both advanced and early-stage TNBC; the first combination of an immune checkpoint inhibitor and chemotherapy has been approved by the FDA for the first-line treatment of PD-L1+ TNBC, and it is likely that the treatment landscape will continue to expand. In this educational on-demand activity based on a recent live web broadcast, a panel of leading experts discusses the current and emerging roles of immunotherapy in TNBC as well as the clinical trial data assessing immunotherapies and immune-based combinations throughout the continuum of TNBC. The practical nuances of patient selection, treatment integration, biomarker testing, and immune-related adverse event management are also explored. Upon completion of this activity, participants should be better able to: Discuss the rationale for use of cancer immunotherapies in the treatment of triple-negative breast cancer (TNBC) specifically and breast cancer more broadly, Assess efficacy, safety, and other key data from clinical trials assessing immunotherapies and immune-based combinations throughout the continuum of TNBC, including in metastatic settings as well as in early-stage disease in neoadjuvant or adjuvant settings, and relevant implications for clinical practice, Evaluate the current and emerging role of immunotherapies in TNBC, nuances of patient selection and treatment integration, biomarker testing when relevant, management of immune-related adverse events, and other practical aspects related to their use in clinical practice, Integrate immune checkpoint inhibitors into treatment plans of patients with TNBC based on latest evidence, indications, recommendations, disease stage, patient and tumor characteristics, and patient needs/preferences.
View all episodes
